HLA-B*5701 screening for susceptibility to abacavir hypersensitivity

Andrew Lucas, Simon Mallal, D Nolan

Research output: Contribution to journalArticlepeer-review

58 Citations (Scopus)


The introduction of highly active antiretroviral therapy (also known as combination therapy) has transformed the nature of HIV infection from a severe and ultimately fatal disease to that of a manageable chronic condition. HIV drugs are highly efficacious, but their use comes at the cost of a range of drug-related adverse events, including severe drug hypersensitivity reactions (HSRs) that have been most notably associated with abacavir and nevirapine therapy. This article discusses the issues of pharmacogenetic screening, in the light of the strong genetic association of the HLA-B*5701 allele and the susceptibility to developing abacavir HSRs. It also presents the screening's impact on clinical practice and discusses the practical considerations that influence the introduction and cost-effectiveness of such screening.
Original languageEnglish
JournalThe Journal of antimicrobial chemotherapy
Publication statusPublished - 22 Feb 2007


Dive into the research topics of 'HLA-B*5701 screening for susceptibility to abacavir hypersensitivity'. Together they form a unique fingerprint.

Cite this